New cell therapy targets 'Hidden' cancer left after chemo
NCT ID NCT07443137
Summary
This early-stage study is testing a personalized cell therapy called rapcabtagene autoleucel (YTB323) for adults with large B-cell lymphoma. It is for patients who have finished their first round of chemotherapy but still have tiny, hard-to-detect amounts of cancer in their blood, putting them at high risk of the cancer coming back. The main goal is to see if this one-time infusion can clear these remaining cancer cells and prevent relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.